MULTIMMUNE GMBH has a total of 21 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are BELLICUM PHARMACEUTICALS INC, CHONGQING FAGEN BIOMEDICAL INC and SAVIENT PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 1 | |
#5 | Belgium | 1 | |
#6 | Canada | 1 | |
#7 | Germany | 1 | |
#8 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Enzymes | |
#6 | Analysing materials | |
#7 | Microbiology |
# | Name | Total Patents |
---|---|---|
#1 | Multhoff Gabriele | 20 |
#2 | Multhoff Joachim | 1 |
Publication | Filing date | Title |
---|---|---|
US2020237860A1 | Hsp70 based combination therapy | |
EP2070947A1 | Therapeutic and diagnostic anti-Hsp70 antibodies | |
US2007280937A1 | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases | |
AU2003227610A8 | Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents | |
DE10313313A1 | Apparatus for the circulation of biological matter in an incubator, especially blood and plasma and blood cells, comprises a rotating basket of a flexible perforated sheet held by a corrugated strip | |
US7517948B2 | Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof |